The use of gene expression signatures is becoming increasingly important in risk stratification and treatment decision-making for patients with early breast cancer. At the St. Gallen Conference 2017 a majority of the panellists took the view that results of gene expression signature tests like Oncotype DX and MammaPrint are prognostic for recurrence of disease within 5 years after surgery. In recent years, the results of MINDACT , TAILOR-X  and the PLAN-B trial  have been published. Based on the results of these trials, almost all panellists (94%) were in favour now of using these gene expression signatures as a decision aid for adjuvant systemic therapy in patients with ER+/Her2-, T1/T2, N0 breast cancer. In case of ER+/Her2-, T3, N0 breast cancer, 75% of the panellists found gene expression signatures to be valuable for determining whether to recommend adjuvant systemic chemotherapy. Also in case of patients with ER+/Her2- (any T) and 1 to 3 positive lymph nodes, a majority (80%) of the panellists was in favour of using a gene expression signature.
In case of a low risk MammaPrint in patients with 1 or 2 positive lymph nodes, 80% of the panellists voted against an indication for adjuvant chemotherapy, irrespective of age. In line with this, 80% of the panellists voted against an indication for adjuvant chemotherapy in patients (older than 50 years) with 1 or 2 positive nodes and an Oncotype DX Recurrence Score <11. Remarkably, 51% of the panellists took the view that patients younger than 50 years, with node-negative disease and an Oncotype DX Recurrence Score of 21 to 25 should be advised adjuvant chemotherapy. This is in contrast with the results of TAILOR-X, which showed little benefit of adjuvant chemotherapy for patients younger than 50 years, node-negative disease and an Oncotype DX Recurrence Score <25. With regard to postmenopausal, node-negative patients having an Oncotype DX Recurrence Score >26, 57% of the panellists agreed that these patients should be offered adjuvant chemotherapy depending on (unfavourable) histopathological parameters and patients preferences, while 39% of the panellists voted that these patients should be offered adjuvant chemotherapy routinely.
- Cardoso F, et al. N Engl J Med 2016; 375:717-729. Sparano JA, et al.
- N Engl J Med 2018; 379:111-121.
- Nitz U, et al. J Clin Oncol. 2019; 37: 799-808.
« Neoadjuvant therapy and residual disease Next Article
Cytoreductive radical prostatectomy: LoMP trial results »
Table of Contents: BCC 2019
St. Gallen Consensus
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.